Reviews/Alcohol and Health/Alcohol raises all-cause mortality
Liver Mortality · ALC-LM-03 · v2
Several large, recent studies that followed people over time found that drinking more alcohol went along with a higher chance of dying from any cause [13][21][27][26][28]. The biggest and best study pooled data on 599,912 drinkers and found the lowest mortality risk at or below about 100 g of alcohol per week, with risk and lost life expectancy climbing at higher amounts [13]. The direction of the finding is firm for heavier drinking, but the picture is softer at low-to-moderate levels: one study of haemodialysis patients found no link [25], and another found a link in UK Biobank but not in the US NHANES group [27]. Several of the studies were done in people who already had a specific disease, which limits how well they speak to the general population. Because all the evidence is observational and cannot fully rule out other explanations, the panel judged the broad, dose-blind wording of the claim to be well-supported in direction but not uniform across every level of drinking.
The corpus consistently shows that higher alcohol intake tracks with higher all-cause mortality across independent prospective cohorts and one individual-participant pooled analysis [13][21][27][26][28]. The best-powered study [13], covering 599,912 current drinkers in 83 prospective studies, found a positive curvilinear association with minimum risk around or below 100 g per week and progressively shorter life expectancy at higher intake. Disease-defined and subgroup cohorts add supporting signal: alcohol carried an aHR of 1.63 (95% CI 1.21-2.19) for all-cause mortality in NHANES-III steatotic liver disease [26], the highest mortality in alcohol-related liver disease (aHR 6.11; 95% CI 1.76-21.19) in a Canadian cohort [28], a 1.23-1.60 fold increase when combined with type 2 diabetes [23], and lower mortality for never-drinkers in food-insecure adults (HR 0.73; 95% CI 0.56-0.97) [24]. The HUNT cohort found increased intake raised mortality but that this was modified by cardiorespiratory fitness [21]. The contested point: The division is at low-to-moderate intake: [13] places minimum mortality risk around or below 100 g per week, so low consumption is not shown to raise mortality, and [25] reports no association in haemodialysis (HRs 0.96 and 1.05, both non-significant). [27] is positive in UK Biobank but finds no significant association in the NHANES cohort, so an unqualified, dose-independent reading of the claim is not uniformly carried.
All 28 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alcohol and Health, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is unqualified by dose, but the corpus's strongest study [13] places minimum all-cause mortality risk 'around or below 100 g per week', so low consumption is not shown to increase mortality.
Null and discordant results exist: [25] finds no association in haemodialysis, and [27] is positive in UK Biobank but reports 'no significant association... in the NHANES cohort', undercutting an unconditional claim at low-moderate intake.
Where it remains uncertain. The strongest study places minimum risk at or below ~100 g per week [13], and low-to-moderate signals are null in haemodialysis [25] and in the NHANES arm of [27], undercutting an unqualified claim.
Aleatory
The association is curvilinear with a threshold around or below 100 g per week [13]; outcome at any given intake varies across individuals rather than being fixed.
Epistemic
Every included study is observational; no trial randomises alcohol exposure, so residual confounding and abstainer or sick-quitter bias remain unresolved [21].
The load-bearing papers from a corpus of 28, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Best-powered evidence (599,912 drinkers): positive dose-response for all-cause mortality above a low threshold
“those who reported drinking >100-≤200 g per week, >200-≤350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively”
Panel auditInternal validity: high · scope of inference: Current drinkers without prior cardiovascular disease in high-income countries.Key limitations: analysis restricted to current drinkers (no abstainer reference) · minimum risk at low, not zero, intake
Independent cohort (HUNT, 24,853) confirms direction for increasing intake
“Increased alcohol intake over the years was associated with an increased risk of mortality.”
Panel auditInternal validity: high · scope of inference: Healthy Norwegian adults with alcohol intake measured at two time points.Key limitations: some relevant confidence intervals include 1.0 · fitness strongly modifies the association
Counter-evidence: null for low-to-moderate alcohol in haemodialysis
“indicating no significant association between all-cause mortality compared with nondrinkers”
Panel auditInternal validity: medium · scope of inference: Adults on maintenance hemodialysis with low-to-moderate alcohol intake.Key limitations: special population (hemodialysis) · heavy drinking rare, so high-exposure inference limited
Co-exposure including elevated alcohol intake was associated with a 1.23 to 1.60 fold increased all-cause mortality versus the non-alcohol reference group.
Panel auditInternal validity: medium · scope of inference: Individuals with steatotic liver disease stratified by diabetes and alcohol.Key limitations: alcohol bundled with T2D in the contrast · no clean abstainer-only reference · SLD population
4 of 28 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, large-cohort support for the direction warrants Likely, but threshold effects and low-moderate nulls prevent an Established verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Low-dose effect unresolved. The claim is unqualified but the threshold in [13] and the nulls in [25] and the NHANES arm of [27] leave low-to-moderate intake unsettled. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A pre-registered pooled analysis of general-population cohorts with lifelong-abstainer reference groups, reporting the dose-response below 100 g per week.
Open question: Does low-to-moderate alcohol intake increase all-cause mortality, or is risk flat below roughly 100 g per week? Why it is still open: [13] places minimum risk at or below 100 g per week and [25] and the NHANES arm of [27] find no association at low-to-moderate levels.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19